US health‑sector Q2 2026 earnings

In late July 2026, NRC Health reported an 11% year‑over‑year increase in total recurring contract value to $151.9 million and a modest 4% rise in revenue, with adjusted EBITDA of $9.4 million (27% margin). NeoGenomics posted earnings per share of $0.05, beating expectations, and generated $201.66 million in revenue, though it recorded a negative net margin of 13.3% and a negative return on equity.

By early August 2026, Nutex Health announced a stronger earnings beat, delivering diluted EPS of $9.38—$4.63 above consensus—net income of $65.8 million, and EBITDA of $94.1 million. Hospital visits in its division rose 9.6% year over year to 49,962, with older‑hospital visits up 6.3%. Despite the robust results, the stock fell $5.33 in after-hours trading. A follow-up confirmed Nutex Health's turnaround, noting that revenue fell 6.3% to $427.2 million while net income and EPS remained at $65.8 million and $9.38 respectively.

Further reporting on 6 August highlighted broader volatility in the sector. Novavax reported a 76% year-on-year decline in second-quarter revenue to $57 million, but raised its 2026 annual revenue forecast to a range of $235 million to $275 million as it shifts strategy toward licensing its vaccine platform and Matrix-M adjuvant through a partnership with Sanofi. Meanwhile, Entera Bio reported an EPS of -$0.14, missing the consensus estimate of -$0.08, contributing to the mixed performance across the U.S. health-sector in Q2 2026.